

Licensed Patents



Licensed patents

The ddRNAi technology patents exclusively licensed from CSIRO offer broad protection for the method of generating hairpin RNA molecules from DNA constructs to silence genes of interest.

Commonly referred to as the "Graham" and "Waterhouse" patent families, these patents have been granted in a range of jurisdictions including the US, Europe, Japan, Australia, China and Korea. With filing dates in 1998 and 1999, respectively, the Graham and Waterhouse patents demonstrate the early establishment of RNAi technology in a range of applications including human therapeutics, providing Benitec's programs in development a competitive edge. Benitec continues to pursue opportunities for identifying improvements to the ddRNAi platform technology relating to human therapeutics. CSIRO is a Benitec shareholder.

In addition to CSIRO's patents, Benitec has also licensed the European patent estate of Galapagos NV relating to RNAi technology. This patent, with filing date in 2002, provides additional protection for RNAi technology in Europe, with sublicensing rights to Benitec in the field of human therapeutics.

Patent Title	Patent No. (Filing date)	Licensor (field)	Status	Link to document
Genetic constructs for delaying or repressing the expression of a target gene (Graham patent family)	US 6,573,099 (19 June 1998)	CSIRO (Exclusive, irrevocable license for human therapeutics)	Graham patent family member; granted 3 June 2003; Re-examination Certificate (US90/008096) issued 8 March 2011	View
Control of gene expression (Graham family patent)	WO199904029 (19 March 1999)	CSIRO (Exclusive, irrevocable license for human therapeutics)	Granted US (8067383, 8168774, 7754697, 8048670, 8053419, 8431547, 9029527), Australia, Canada, Europe (under opposition), UK, Hong Kong, India, Japan, Korea, Mexico, New Zealand, Singapore, South Africa Pending US, Brazil, Europe, Japan, Mexico	View
Methods and means for obtaining modified phenotypes (Waterhouse patent family)	WO1999053050 (7 April 1999)	CSIRO (Exclusive, irrevocable license for human therapeutics)	Granted US, Australia, China, Europe, New Zealand Pending US, Canada, Europe, Japan	View
siRNA knockout assay method and constructs	EP 1444346 (29 August 2002)	Galapagos NV (Non-exclusive license for human therapeutics and diagnostics)	Granted Europe	View
Methods for detecting and modulating the sensitivity of tumour cells to anti-mitotic agents (Lung cancer)	WO2008106730 (5 March 2008)	NewSouth Innovations (Exclusive license for human therapeutics and diagnostics)	Granted Australia, China, Hong Kong, Singapore Pending Canada, China, Europe, Hong Kong, Israel, India, Japan, US	View

INTELLECTUAL PROPERTY

- Patent Summary
- Benitec Patents
- Licensed Patents**
- Trademarks

Receive Updates via Email



Keep up with programs, analyst reports, announcements, events and more. Choose what you want.

YES PLEASE

Contact Us



Ask about our technology, licensing, partnering and more. Call or email us.

YES PLEASE

TECHNOLOGY
What is ddRNAi?
What is RNAi?
siRNA vs shRNA
Publications
Science Glossary

INTELLECTUAL PROPERTY
Overview
Benitec Patents
Licensed Patents
Trademarks

PIPELINE
In-house programs
Licensed programs
Licensing options
Partners

ABOUT US
Our story
Management
Board
Corporate Directory

INVESTOR CENTRE
Why Invest in Benitec?
Stock Info
ASX Announcements
Email Updates
Presentations
Analyst Coverage
Reports
Investor Fact Sheet
Shareholder Meetings
Investor FAQ
ADR Trading

Receive Updates via Email



BENITEC
BIOPHARMA
silencing genes for life™

Benitec BioPharma
1-15 Barr St
Balmain (Sydney)
NSW Australia
P. +61 2 9555 6986